NYSE:LLY 26 December 2025 - 4 January 2026

Eli Lilly and Company shares closed up 0.53% at $1,080.36 on Friday and were down 0.17% in after-hours trading at $1,078.50.

Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, according to data from healthcare research firm 3 Axis Advisors. The median increase is about 4%, and the figures do not reflect rebates or other discounts. The same dataset showed drugmakers also plan to cut list prices on about nine medicines, including a more than 40% reduction for diabetes drug Jardiance, sold by Boehringer Ingelheim and Eli Lilly, after Medicare negotiated a lower price for 2026. Reuters

Eli Lilly shares slipped 0.5% in Wednesday’s final session of 2025, closing at $1,074.68, before U.S. markets shut for the New Year’s Day holiday. StockAnalysis+1

Eli Lilly shares ended the holiday week little changed after South Korean biotech ABL Bio said it would receive $55 million in funding from the U.S. drugmaker under a research collaboration. PR Newswire

Eli Lilly and Company heads into the final trading stretch of 2025 with its stock near record territory and investors laser-focused on three forces that can move the shares quickly: the accelerating battle for obesity and diabetes drug dominance, the policy and pricing machinery starting to reshape access to GLP‑1 treatments, and Lilly’s pipeline and business-development cadence beyond today’s blockbusters.

New York — As of 7:56 p.m. ET on Friday, December 26, 2025, Eli Lilly and Company is coming off a session that left the stock hovering around $1,077.75, essentially flat on the day after a narrow trading range.

Eli Lilly and Company heads into the Friday, Dec. 26, 2025 U.S. market open with investors balancing two powerful forces: policy-driven price pressure on GLP‑1 drugs and pipeline-driven growth potential that keeps Lilly at the center of the obesity and diabetes mega-trend.